12:00 - 12:30

NIHR Manchester BRC Networking and Webinar: Generic aspects of study design for experimental

Webinar or Nowgen Centre, 29 Grafton Street, Manchester M13 9WU

NIHR Manchester BRC Networking and Webinar Series

The BRC’s Rapid Translational Incubator signposts researchers to appropriate support when setting up and running trials and studies in GM. NIHR Manchester BRC now runs networking events and webinars to discuss solutions to common problems in a supportive peer network. The webinars provide an overview of the support available in Manchester and highlight an overview of processes/people to contact.

Theme: Generic aspects of study design for Experimental Medicine studies and trials

Choosing the most appropriate study design is one of the most important aspects to consider when developing a clinical trial or study. It is rarely possible to rescue a poorly designed study. In this webinar, Chris Sutton will talk about the main aspects to consider for a robust study design and when you might involve a CTU in your proposed study or trial.

Speaker:

Dr Chris Sutton, Senior Lecturer in Clinical Trial Statistics, Centre for Biostatistics, The University of Manchester

Chris is Deputy Director (Methodology) and Lead Statistician for Manchester CTU. He has an interest in improving health through improving trials and collaborates widely on complex trials in various disciplines, with specific interest in the topics of stroke, musculoskeletal and mental health.

Host: Matt Krebs, Senior Lecturer in Medical Oncology, The Christie NHS Foundation Trust. BRC Cancer Precision Medicine theme

Date/time: Thursday 17 October, 12-12:30

Register for the webinar here.

Register to attend in person (Nowgen Centre, Grafton Street, M13 9WU) via Eventbrite

The webinar recording will be available on the BRC website afterwards.

Event contact: Zoe Talks

Email: Zoe.Talks@mft.nhs.uk

Telephone: +44 (0)161 701 0720

For more information visit https://www.manchesterbrc.nihr.ac.uk

Follow and contribute @ManchesterBRC #BRCRTI

Back to top